US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

City Therapeutics (CTY): Big-Name Backers, Early-Stage Science and an Aftermarket Test

IPOs and Secondary Offerings

Equity Capital Markets

City Therapeutics / Equity Capital Markets

<ul>
<li>City Therapeutics is seeking an $856 million to $956 million valuation in an IPO, offering 9.72 million shares at $17–$19 each.</li>
<li>The RNAi-focused biotech has advanced three programs toward the clinic, backed by experienced leadership and collaborations with Bausch + Lomb and Biogen.</li>
<li>Despite strong industry validation, City remains an early-stage, pre-revenue company with limited clinical data and substantial development and funding risks.</li>
</ul>


City Therapeutics is seeking an $856 million to $956 million valuation in an IPO, offering 9.72 million shares at $17–$19 each.
The RNAi-focused biotech has advanced three programs toward the clinic, backed by experienced leadership and collaborations with Bausch + Lomb and Biogen.
Despite strong industry validation, City remains an early-stage, pre-revenue company with limited clinical data and substantial development and funding risks.


City Therapeutics (CTY): RNAi Ambitions, City Therapeutics Launches IPO With $956M Target Valuation